CICC’s initiation is a contrarian bullish signal from a mid-tier firm, but lacks confirmation from EPS revisions or institutional momentum. Monitor for follow-up upgrades or Q1 earnings catalysts before positioning.
Price Chart
Executive Summary
CICC initiates Pfizer (PFE) at Outperform with a $33 price target, implying 15.6% upside from the current $28.55. The move contrasts with a divided analyst base: 26 analysts show a mean PT of $28.58 and median of $27, with 37% Buy, 31% Hold, and 32% Sell ratings. CICC’s accuracy is 55% (17/31 calls correct), below top-tier firms like Morgan Stanley (71%, 5/7) and Cantor (59%, 10/17). Recent analyst activity includes one upgrade and no downgrades in 30 days. EPS estimates are trending down: -8bps in +1q EPS over 30 days. Institutional flows are mixed — Renaissance Technologies exited while Two Sigma increased position 27x. No insider trades or short interest data available. Earnings date not disclosed.
Impact Score
Recent Analyst Activity
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| 2026-04-16 | CICC | initiate | Outperform | $33.00 |
| 2026-04-13 | UBS | maintain | Neutral | $27.00 |
| 2026-04-10 | Morgan Stanley | maintain | Equal-Weight | $28.00 |
| 2026-04-09 | B of A Securities | maintain | Neutral | $26.00 |
| 2026-03-24 | Guggenheim | maintain | Buy | — |
| 2026-03-17 | HSBC | maintain | Buy | — |
| 2026-03-02 | Argus Research | upgrade | Buy | — |
| 2026-02-25 | RBC Capital | initiate | Underperform | $25.00 |
| 2026-02-20 | Barclays | initiate | Underweight | $25.00 |
| 2026-02-09 | Freedom Broker | maintain | Buy | — |
Over the past 30 days, there has been 1 upgrade (Argus Research) and 0 downgrades. EPS revisions are negative: +1q EPS estimate down 8 cents over 30 days (from $0.7096 to $0.7017), +1y down 8 cents (from $2.831 to $2.823), indicating weakening sentiment despite isolated bullish calls.
Firm Track Record — CICC
CICC accuracy: 55% on 31 calls | avg return: 1.4%
Industry benchmark: mean 51% ± 11%. Top tier: ≥61% (mean + 1σ). Based on 7 firms with ≥5 scored calls.
| Firm | Accuracy | Calls | Avg Return | vs Average |
|---|---|---|---|---|
| Morgan Stanley | 71% | 5/7 | 4.2% | top tier |
| B of A Securities | 67% | 2/3 | -0.1% | top tier |
| Cantor Fitzgerald | 59% | 10/17 | 1.8% | above average |
| Citigroup | 50% | 1/2 | -5% | below average |
| Barclays | 50% | 1/2 | -1.2% | below average |
| Guggenheim | 40% | 2/5 | -1.4% | below average |
| UBS | 40% | 2/5 | -2.7% | below average |
CICC has a 55% accuracy rate (17/31 calls correct), below Morgan Stanley (71%, 5/7) and B of A Securities (67%, 2/3), but above Guggenheim (40%, 2/5) and UBS (40%, 2/5). Its average return of +1.4% ranks in the middle tier. Top-performing firm is Morgan Stanley with +4.2% avg return.
Earnings Estimates
| Period | EPS Est. | EPS Range | Revenue | Revisions (7d) |
|---|---|---|---|---|
| +1q | $0.70 | $0.61 — $0.91 | $14.5B | ↑0 ↓0 |
| +1y | $2.82 | $2.48 — $3.03 | $58.9B | ↑1 ↓0 |
| 0y | $2.96 | $2.80 — $3.17 | $61.2B | ↑1 ↓0 |
| 0q | $0.73 | $0.64 — $0.92 | $13.9B | ↑1 ↓0 |
Cross-Platform Signals
Institutional activity is mixed: Two Sigma increased its stake by 2734.9%, while Renaissance Technologies fully exited a $1.8B position. Norges Bank both entered and later exited — suggesting volatility. No insider trades reported. Congressional buys: Susan Collins (R) bought $15K–$50K on Feb 3; Gilbert Cisneros (D) bought $1K–$15K on Feb 10. Signal divergence: analyst initiation is bullish, but institutional and EPS trends are neutral-to-weak.
Investment Themes
Documents Analyzed
Report based on filing metadata.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 13, 2026 7w ago | Court Ruling | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.59 (+2.95%) |
Aug 12, 2026 7w ago | Insider Buy | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.59 (+2.95%) |
Aug 12, 2026 7w ago | Insider Cluster | $26.80 $27.72 | ▲ +3.43% | ▲ +5.18% | $27.59 (+2.95%) |
Aug 6, 2026 8w ago | Insider Cluster | $26.20 $28.81 | ▲ +9.95% | ▲ +9.35% | $27.59 (+5.31%) |
Aug 5, 2026 8w ago | Insider Cluster | $26.20 $28.81 | ▲ +9.95% | ▲ +9.35% | $27.59 (+5.31%) |
Aug 4, 2026 8w ago | 8-K | $25.41 $28.55 | ▲ +12.36% | ▲ +13.60% | $27.59 (+8.58%) |
Jul 31, 2026 9w ago | Court Ruling | $25.01 $27.96 | ▼ −11.80% | ▼ −8.81% | $27.59 (−10.32%) |
Jul 24, 2026 10w ago | Court Ruling | $24.54 $28.07 | ▲ +14.38% | ▲ +10.76% | $27.59 (+12.43%) |
Jul 6, 2026 12w ago | ANALYST-DOWNGRADE | $23.72 $25.01 | ▼ −5.44% | ▼ −6.00% | $27.59 (−16.32%) |
Jun 18, 2026 15w ago | 8-K | $25.21 $25.14 | ▼ −0.28% | ▼ −0.81% | $27.59 (+9.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access